Loading...
•
Jun 30, 2020
Avadel Q2 2020 Earnings Report
Reported second quarter 2020 financial results, including revenue of $10.1 million and net income of $30.9 million.
Key Takeaways
Avadel Pharmaceuticals reported second quarter results with a focus on the development of FT218. They completed a public equity offering for $125.0 million and sold their legacy portfolio for $42.0 million. Net income for the quarter was $30.9 million, or $0.49 per diluted share.
Completed pre-NDA meeting with the FDA for FT218.
Completed a public equity offering for gross proceeds of $125.0 million.
Sold legacy portfolio of sterile injectable drugs for $42.0 million.
Net income for the second quarter of 2020 was $30.9 million, or $0.49 per diluted share.
Forward Guidance
The company's highest priority remains the completion and filing of their once-nightly FT218 NDA.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...